Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
May 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
Feb 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
Jan 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia |
Apr 2021 |
Transplantation and Cellular Therapy |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
Eltrombopag in children with severe aplastic anemia |
Apr 2021 |
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
Apr 2019 |
Blood |
Aplastic Anemia |
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Jun 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Oct 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis |
Dec 2023 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |